CiMaas BV is a biotech company developing cellular immunotherapy for specific groups of cancer patients. CiMaas focuses on the development of two unique products: a cancer vaccine using the patient’s own immune (dendritic) cells and the production of donor natural killer cells. These methods can help to treat many oncological diseases.
Bellicum Pharmaceuticals is a biopharma company developing novel cellular immunotherapies for various forms of cancer (both hematological and solid tumors), as well as orphan inherited blood disorders.
Transposagen is a biotech company specialized in genetic engineering through several technologies (XTNTALEN site-specific nucleases for knockouts and knock-ins, piggyBac transposon system for transgenesis, Footprint-Free gene editing vectors, etc…).
Cellectis is a biotech company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART).
Medigene is a biotech company focusing on the development of personalized T-cell immunotherapies. Medigene develops highly innovative treatment platforms concentrating on haematological malignancies, cancer and autoimmune diseases.
Immunocore is a clinical-stage biotech company focused on the development of novel T cell receptor-based drugs to treat cancers and viral diseases. Immunocore is the world-leader in engineering T Cell Receptors (TCRs) and link them to an antibody fragment (scFv). Its first product candidate, IMCgp100, entered clinical trials in patients with metastatic melanoma.
